The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination therapy (SOL+BV; SOLA) in patients with unresectable metastatic colorectal cancer (mCRC).
Takeshi Kato
Honoraria - Chugai Pharma; Chugai Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical; Yakult; Yakult
Tomohiro Nishina
Honoraria - Chugai Pharma; Chugai Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical; Yakult; Yakult
Kentaro Yamazaki
Honoraria - Chugai Pharma; Chugai Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical; Yakult; Yakult
Research Funding - Chugai Pharma; Chugai Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical
Takayuki Yoshino
Honoraria - Chugai Pharma; Chugai Pharma; Yakult; Yakult
Yoshinori Miyata
No relevant relationships to disclose
Taito Esaki
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult
Research Funding - Chugai Pharma; Taiho Pharmaceutical; Yakult
Toshikazu Moriwaki
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult
Ichinosuke Hyodo
Consultant or Advisory Role - Chugai Pharma; Taiho Pharmaceutical; Yakult
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult
Research Funding - Chugai Pharma; Taiho Pharmaceutical; Yakult